On the other hand, according to the positive effects of AR on ER+ cell proliferation, preclinical studies have confirmed that antiandrogens (i.e., bicalutamide and enzalutamide) inhibit ER+ BC growth by abrogating AR nuclear translocation. This evidence concerns the gene AR and breast cancer.